[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].
Zhongguo Fei Ai Za Zhi
; 23(3): 136-141, 2020 03 20.
Article
in Chinese
| MEDLINE | ID: covidwho-1445
ABSTRACT
Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Disease Outbreaks
/
Immunocompromised Host
/
Coronavirus Infections
/
Betacoronavirus
/
Lung Neoplasms
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Asia
Language:
Chinese
Journal:
Zhongguo Fei Ai Za Zhi
Journal subject:
Neoplasms
Year:
2020
Document Type:
Article
Affiliation country:
J.issn.1009-3419.2020.03.02
Similar
MEDLINE
...
LILACS
LIS